{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Stringent Complete Response (sCR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Very Good Partial Response (VGPR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Partial Response (PR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Complete Response (CR):\n\nNegative immunofixation of serum and urine Normalization of FLC ratio \\< 5% plasma cells in bone marrow Disappearance of any soft tissue plasmacytomas\n\nStringent Complete Response (sCR):\n\nCR, as above, with absence of clonal cells in bone marrow\n\nPartial Response (PR):\n\nOne of the following:\n\n1. A ≥ 50% reduction of measurable serum M-protein.\n2. A reduction in 24h measurable urinary M-protein by ≥ 90% or to \\<200 mg per 24h.\n3. A ≥ 50% decrease in the difference between involved and uninvolved FLC levels.\n4. ≥50% reduction in bone marrow plasma cells is required in place of Mprotein, provided baseline percentage was ≥ 30%\n5. A ≥50% reduction in the size of soft tissue plasmacytomas.\n\nVery Good Partial Response (VGPR):\n\nPR as defined above in addition to having serum and urine M-component detectable by immunofixation but not on electrophoresis.","groups":[{"description":"Participants were accrued at 50 mg/m\\^2 dose level after December 30, 2009 addendum. Participants to receive 50 mg/m\\^2 dinaciclib IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Phase II"}],"paramType":"NUMBER","populationDescription":"Fifteen of the 16 accrued Phase II participants were analyzed (1 participant was a protocol violation).","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Number of Confirmed Responses, Defined to be an sCR, CR, VGPR, or PR Noted as the Objective Status on Two Consecutive Evaluations.","type":"PRIMARY","unitOfMeasure":"participants"}